News >

Juno CAR T Cell Therapy Receives Breakthrough Designation for ALL

Silas Inman @silasinman
Published: Monday, Nov 24, 2014

Hans Bishop

Hans Bishop

The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), according to a statement released by Juno Therapeutics, the company developing the adoptive T cell therapy. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication